secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001386570-25-000015
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY
------------------------------------------------------------------------

- Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.
- CEO cites FDA reversal on DSHEA drug preclusion rule for NMN as potential awareness driver.
- Press release notes every NMN supplement tested infringes on Niagen's patent portfolio.
- Niagen (patented NR) claims superior bioavailability vs. NMN, with three in four NMN products failing label claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/0001386570-25-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000138657025000015/cdxc-20251006.htm
  HTML page:      https://secwatch.observer/filing/0001386570-25-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer